[1] ARSLAN S, UGURLU S, BULUTG, et al.The association between plasma D-dimer levels and community acquired pneumonia[J].Clinics(Sao Paulo), 2010, 65(6):593.
[2] NASTASIJEVIĆBOROVAC D, RADJENOVIĆPETKOVIĆT, PEJČIĆ T, et al.Role of D-dimer in predicting mortality in patients with community acquired pneumonia[J].Med Glas(Zenica), 2014, 11(1):37.
[3] SNIJDERS D, SCHOORL M, SCHOORLM, et al.D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia.A secondary analysis of a randomized clinical trial[J].Eur J Intern Med, 2012, 23(5):436.
[4] KILIÇ H, KANBAY A, KARALEZLI A, et al.Clinical characteristics of 75 pandemic H1N1 influenza patients from Turkey:risk factors for fatality[J].Turk J Med Sci, 2015, 45(3):562.
[5] 国家卫生健康委员会, 国家中医药管理局.新型冠状病毒肺炎诊疗方案(试行第六版)[J].中国病毒病杂志, 2020, 10(2):88.
[6] WHO.Clinical management to severe acute respiratory infection when Novel coronavirus(nCoV)infection is suspect ed: interim guidance[EB/OL].(2020-02-26).https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
[7] HUANG C, WANG Y, LI X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J].Lancet, 2020, 395(10223), 497.
[8] FINLAY BB, MCFADDEN G.Anti-immunology:evasion of the host immune system by bacterial and viral pathogens[J].Cell, 2006, 124(4):767.
[9] 王胜云, 陈德昌.降钙素原和C-反应蛋白与脓毒症病人病情严重程度评分的相关性研究及其对预后的评估价值[J].中华危重病急救医学, 2015, 27(2):97.
[10] HUI DSC, ZUMLA A.Severe acute respiratory syndrome:historical, epidemiologic, and clinical features[J].Infect Dis Clin North Am, 2019, 33(4):869.
[11] CHEN N, ZHOU M, DONG X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study[J].Lancet, 2020, 395(10223):507.
[12] WANG D, HU B, HU C, et al.Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus Infected Pneumonia in Wuhan, China[J].JAMA, 2020, 323(11):1061.
[13] WANG FS, ZHANG C.What to do next to control the 2019-nCoV epidemic?[J].Lancet, 2020, 395(10222):391.
[14] BHUIYANMU, BLYTH CC, WEST R, et al.Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children[J].BMC Pulm Med, 2019, 19(1):71.
[15] ESPOSITOS, BIANCHINI S, GAMBINOM, et al.Measurement of lipocalin-2 and syndecan-4 levels to differentiate bacterial from viral infection in children with community-acquired pneumonia[J].BMC Pulm med, 2016, 16(1):103.
[16] ESPOSITO S, DI GANGI M, CARDINALE F, et al.Sensitivity and specificity of soluble triggering receptor expressed on myeloid Cells-1, Midregional Proatrial natriuretic peptide and Midregional Proadrenomedullin for distinguishing etiology and to assess severity in community-acquired pneumonia[J].PLoS One, 2016, 11(11):e0163262.
[17] NAYDENOVA E, TSANA S A, HOWIES, et al.The power of data mining in diagnosis of childhood pneumonia[J].J R Soc Interface, 2016, 13(120):20160266.
[18] BURGMEIJER EH, DUIJKERS R, LUTTER R, et al.Plasma cytokine profile on admission related to aetiology in community-acquired pneumonia[J].Clin Respir J, 2019, 13(10):605.
[19] MILBRANDT EB, READE MC, LEE MJ, et al.Prevalence and significance of coagulation abnormalities in community-acquired pneumonia[J].Mol Med, 2009, 15(11/12)::438.
[20] 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等.新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)[J].中华医学杂志, 2020, 100(11):808.
[21] ARACHCHILLAGE DRJ, LAFFAN M.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J].J Thromb Haemost, 2020, 18(5):1233.
[22] ZHOU F, YU T, DU R, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J].Lancet, 2020, 395(10229):1054.
[23] 张洁, 谢立新, 谢良地.D-二聚体对社区获得性肺炎病人病情严重程度及预后的评估价值[J].中华危重病急救医学, 2016, 28(9):769.
[24] LEVI M.The coagulant response in sepsis and inflammation[J].Hamostaseologie, 2010, 30(1):14.